

Supplementary Table S1. Number (N) and percent (%) of therapeutic exposures used in the development of the tree model within each final treatment combination category.

Treatment Combination Categories	CRT		Platinum Agents		Steroids		Anthra-cyclines		Alkylating Agents		Plant Alkyloids	
	N	%	N	%	N	%	N	%	N	%	N	%
Platinum & CRT (N=12)	12	100.0	12	100.0	1	8.3	0	0	9	75.0	11	91.7
Platinum & anthracycline; no CRT (N=16)	0	0.0	16	100.0	0	0.0	16	100.0	16	100.0	2	12.5
Platinum; no CRT or anthracycline (N=16)	0	0.0	16	100.0	0	0.0	0	0.0	2	12.5	12	75.0
Steroids; no platinum (N=140)	16	11.4	0	0.0	140	100	128	91.4	126	90.0	125	89.3
No platinum, steroid, or alkylating agent (N=44)	13	29.5	0	0.0	0	0.0	16	36.4	0	0.0	30	68.2
Alkylating agents; no platinum, steroid, or anthracycline (N=8)	0	0.0	0	0.0	0	0.0	0	0.0	8	100.0	7	87.5
Alkylating agent & anthracycline; no platinum or steroid (N=23)	2	8.7	0	0.0	0	0.0	23	100.0	23	100.0	22	95.7
Surgery alone (N=60)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Supplementary Table S2: Cumulative dose categories of chemotherapy agents.

Chemotherapy	Dose Range (mg/m²)	Frequency	Percent
Anthracyclines	33-150	93	29.3
	>150	88	27.8
	None	136	42.9
Cisplatinum	250-450	12	3.8
	>450	11	3.5
	None	294	92.7
Carboplatinum	338-3348	11	3.5
	>3348	10	3.1
	None	298	93.4
Total Platinum	84.5-560	22	6.9
	>560	21	6.6
	None	275	86.5
Cyclophosphamide	400-1999	49	15.5
	2000-4000	69	21.8
	>4000	51	16.1
	None	147	46.5
Ifosfamide	150-57270	14	4.4
	>57270	14	4.4
	None	291	91.2
Methotrexate, IT Administration Route	24-254	60	19.1
	>254	59	18.7
	None	196	62.2
Methotrexate, non-IT Administration Route	192-2180	22	8.9
	>2180	21	8.5
	None	204	82.6
VP-16	30-2000	35	11.2
	>2000	30	9.6
	None	249	79.3
Steroids	200-6399	43	13.9
	6401-9253.33	43	13.9
	>9253.32	45	14.6
	None	178	57.6